Health-related quality of life: a pivotal endpoint in benefit assessment of medical procedures;Gesundheitsbezogene Lebensqualität – ein zentraler patientenrelevanter Endpunkt in der Nutzenbewertung medizinischer Maßnahmen

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 58, Issue 3, 2015, Pages 283-290

  Bullinger, M ^a   Blome, C ^a   Sommer, R ^a   Lohrberg, D ^a   Augustin, M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

AMNOG; Early assessment of benefit; Measurement instruments; Medical products; Quality of life

Indexed keywords

BIOASSAY; COST BENEFIT ANALYSIS; DRUG APPROVAL; EVIDENCE BASED MEDICINE; GERMANY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROCEDURES; QUALITY OF LIFE; QUESTIONNAIRE; STANDARDS; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DRUG APPROVAL; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; GERMANY; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84925466758     PISSN: 14369990     EISSN: 14371588     Source Type: Journal    
DOI: 10.1007/s00103-014-2107-0     Document Type: Article

References (46)

1. Sozialgesetzbuch (SGB) Fünftes Buch (V) -Gesetzliche Krankenversicherung - (Artikel 1 desGesetzes v. 20. Dezember 1988, BGBl. I S. 2477) SGB 5Ausfertigungsdatum: 20.12.1988 Stand: Zuletzt geändert durch Art. 5 G v. 2.12.2014 I 1922
2. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2013) Allgemeine Methoden: Version 4,1. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, Köln
3. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2014) Allgemeine Methoden. Entwurf für Version 4.2. https://www.iqwig.de/download/IQWiG_Methoden_Entwurf-fuer-Version-4-2.pdf. Zugegriffen: 11. August 2014
4. Ruof J, Knoerzer D, Dünne A, Dintsios C, Staab T, Schwartz FW (2014) Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany. Health Policy. doi:10.1016/j.healthpol.2014.08.004
5. Patrick DL, Burke LB, Powers JH et al (2007) Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 10(2):125–137
6. Patrick DL, Burke LB, Gwaltney CJ et al (2011) Content validity – establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1 – Eliciting concepts for a new PRO instrument. Value Health 14(8):967–977
7. Fayers PM, Machin D (2007) Quality of life. The assessment, analysis and interpretation of patient-reported outcomes, 2. Aufl. Wiley, Chichester
8. Patrick DL, Deyo RA (1989) Generic and disease-specific measures in assessing health status and quality of life. Med Care 27(3):217–232
9. Bullinger M, Power M, Aaronson NK, Cella D, Anderson RT (1996) Creating and evaluating cross-cultural instruments. In: Spilker B (Hrsg) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven, Philadelphia, S 659–668
10. The WHOQOL Group (1993) Study protocol for the World Health Organization project to develop a quality of life assessment instrument (WHOQOL). Qual Life Res 2(2):153–159
11. Ware JE (1996) The SF-36 health survey. In: Spilker B (Hrsg) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven, Philadelphia, S 337–346
12. Bullinger M (2014) Das Konzept der Lebensqualität in der Medizin – Entwicklung und heutiger Stellenwert. Z Evid Fortbild Qual Gesundh 108:97–103
13. Bullinger M, Ravens-Sieberer U (1995) Grundlagen, Methoden und Anwendungsgebiete der Lebensqualitätsforschung bei Kindern. Prax Kinderpsychol Kinderpsychiatr 44:391–399
14. Matza LS, Patrick DL, Riley AW et al (2013) Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health 16(4):461–479
15. Ravens-Sieberer U, Gosch A, Rajmil L et al (2005) The KIDSCREEN-52 quality of life measure for children and adolescents: development and first results from a european survey. Exp Rev Pharmacoecon Outcome Res 5(3):353–364
16. Varni JW, Burwinkle TM, Lane MM (2005) Health-related quality of life measurement in pediatric clinical practice: an appraisal and precept for future research and application. Health Qual Life Outcomes 3:34
17. The DISABKIDS Group Europe (2006) The DISABKIDS Questionnaires – Quality of life questionnaires for children with chronic conditions. Handbook. Pabst Science Publishers, Lengerich
18. The European QoLISSY Study Group (2013) The QoLISSY questionnaire – user manual. Pabst Science Publishers, Lengerich
19. Mackensen S von, Bullinger M (2004) Development and testing of an instrument to assess the Quality of life of children with haemophilia in Europe (Haemo-QoL). Haemophilia 10(1):17–25
20. Mühlan H, Bullinger M, Power M, Schmidt S (2008) Short forms of subjective quality of life assessments from cross-cultural studies for use in surveys with different populations. Clin Psychol Psychother 15(3):142–153. doi:10.1002/cpp.573
21. Ravens-Sieberer U, Heilmann M, Walleser S (2000) Assessment of quality of life in young children with a computer assisted touch screen Program (CAT-screen) – reliability, validity and feasibility. 7th annual conference of the International Society for Quality of Life Research (ISOQOL). Qual Life Res 9(3):298
22. Cella D, Yount S, Rothrock N et al (2007) The patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years. Med Care 45(5 Suppl 1):3–11
23. World Health Organization International Classification of Functioning, Disability and Health (ICF) (2005) http://www.dimdi.de/static/de/klassi/icf/index.htm. Zugegriffen: 11. August 2014
24. The EuroQol Group (1990) EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 16(3):199–208
25. Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727–1736
26. Horsman J, Furlong W, Feeny D, Torrance G (2003) The health utilities index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 1(1):54
27. Augustin M, Radtke MA, Zschocke I et al (2009) The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res 301(8):561–571
28. Augustin M, Blome C, Zschocke I et al (2012) Benefit evaluation in the therapy of chronic wounds from the patients’ perspective – development and validation of a new method. Wound Repair Regen 20(1):8–14
29. Blome C, Augustin M, Heyer K et al (2014) Evaluation of patient-relevant outcomes of lymphedema and lipedema treatment: development and validation of a new benefit tool. Eur J Vasc Endovasc Surg 47(1):100–107
30. Morfeld M, Kirchberger M, Bullinger M (2011) SF-36 Fragebogen zum Gesundheitszustand. Deutsche Version des Short Form-36 Health Survey 2, ergänzte und bearbeitete Version (Manual). Hogrefe, Göttingen
31. Aaronson NK, Ahmedzai S, Bergman B et al (1993) The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376
32. Webster K, Cella D, Yost K (2003) The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1:79
33. Bradley C (1994) Diabetes treatment satisfaction questionnaire. In: Bradley C (Hrsg) Handbook of psychology and diabetes. Harwood Academic Publishers, Chur, S 111–132
34. Aaronson NK, Ahmedzai S, Bergman B et al (1993) The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376
35. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579
36. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655
37. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ (1997) Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50(6):920–928
38. Webster K, Cella D, Yost K (2003) The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1:79
39. Mangione CM, Lee PP, Gutierrez PR et al (2001) Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol 119(7):1050–1058
40. Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann BP (1998) Development and cross-cultural translation of a 31-item quality of life questionnaire (QOLIE-31). Epilepsia 39:81–88
41. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM (1994) Development of a type 2 diabetes symptom checklist: a measure of symptom severity Diabet Med 11(3):253–261
42. Jones PW, Quirk FJ, Baveystock CM (1991) The St George’s respiratory questionnaire. Respir Med 85(2):25–31
43. Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353–365
44. Gemeinsamer Bundesausschuss (G-BA) (Frühe) Nutzenbewertung nach § 35a SGB V. Übersicht der Wirkstoffe. https://www.g-ba.de/informationen/nutzenbewertung/. Zugegriffen: 11. August 2014
45. Bullinger M (2006) Methodische Grundlagen und Aspekte der Lebensqualität. [Methodological basis and aspects of quality of life]. Dtsch Med Wochenschr 131:5–7
46. Bullinger M (2002) Lebensqualität: ein neues Thema in der Medizin? Zentralbl Gynäkol 124:153–156